Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Petrylak

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in hormone-refractory prostate cancerD P Petrylak
Current Oncology Reports|August 8, 2001
Combination therapy in hormone-refractory prostate cancerD P Petrylak
Nature Medicine|August 1, 1995
Metastases suppressors and prostate cancerD P Petrylak
Urology|December 22, 1999
Chemotherapy for advanced hormone refractory prostate cancerD P Petrylak
Current Oncology Reports|June 8, 2001
Transitional cell carcinoma of the bladder: new approaches to the treatment of advanced diseaseD P Petrylak
Cancer Treatment and Research|January 1, 1996
Therapy for hormone-resistant prostate cancer: no longer a mythD P Petrylak, B Abi-Rashid
Prostate Cancer and Prostatic Diseases|December 24, 2002
Refractory disease, new horizons and patient-physician relationshipsL M Glode, D P Petrylak, L M Glode
Cancer Research|January 1, 1985
Stimulation of Rauscher leukemia virus DNA polymerase DNA-directed DNA synthesis by cationic trypanocides and polyaminesS L Marcus, D P Petrylak, J J Burchenal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladderD P Petrylak, H I Scher, V Reuter, et al.
Cancer|December 15, 1992
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapyD P Petrylak, H I Scher, Z Li, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in hormone-refractory prostate cancerD P Petrylak
Current Oncology Reports|August 8, 2001
Combination therapy in hormone-refractory prostate cancerD P Petrylak
Nature Medicine|August 1, 1995
Metastases suppressors and prostate cancerD P Petrylak
Urology|December 22, 1999
Chemotherapy for advanced hormone refractory prostate cancerD P Petrylak
Current Oncology Reports|June 8, 2001
Transitional cell carcinoma of the bladder: new approaches to the treatment of advanced diseaseD P Petrylak
Cancer Treatment and Research|January 1, 1996
Therapy for hormone-resistant prostate cancer: no longer a mythD P Petrylak, B Abi-Rashid
Prostate Cancer and Prostatic Diseases|December 24, 2002
Refractory disease, new horizons and patient-physician relationshipsL M Glode, D P Petrylak, L M Glode
Cancer Research|January 1, 1985
Stimulation of Rauscher leukemia virus DNA polymerase DNA-directed DNA synthesis by cationic trypanocides and polyaminesS L Marcus, D P Petrylak, J J Burchenal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladderD P Petrylak, H I Scher, V Reuter, et al.
Cancer|December 15, 1992
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapyD P Petrylak, H I Scher, Z Li, et al.
Pageof 5